Genital wart. Anogenital (venereal) warts
Conditions
Interventions
Intervention 1: Intervention group: After explaining the process for patients and taking informed written consent from them, the topical gel of Ingenol mebutate 0.05% is used on the wart surface wi
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with untreated anogenital persistent to therapy wart
Exclusion criteria
Exclusion criteria: Immunosuppressed patients Patients with drug reaction Patients with other sexually transmitted diseases like herpes in the anogenital area Pregnancy and lactation Under 18 y/o Treatment with other choices like cryotherapy or imiquimod in the last 4 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients with untreated or resistant anogenital warts. Timepoint: Following up at 1,2,3 weeks and 1,3,5 months after the firs treatment. Method of measurement: Physical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| The frequency of repeating treatment until complete cure. Timepoint: Weekly follow up until 3 weeks, then follow up at 1,3 and 5 months after the first course of treatment. Method of measurement: Physical examination.;Duration of disease. Timepoint: The number of months the warts developed. Method of measurement: History.;Number of warts. Timepoint: Number of warts at the beginning of treatment and follow up. Method of measurement: Clinical counting.;Side effects after treatment. Timepoint: 7, 14, 21, 30,90 and 180 days after treatment. Method of measurement: Inspection and clinical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZeinab Bizaval
Shahid Beheshti University of Medical Sciences
Outcome results
None listed